BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that Aetna Inc., one of the nation’s leading providers of health care insurance, has determined that AlloMap® is “medically necessary” for monitoring rejection in heart transplant recipients more than one year after a heart transplant. With this determination, Aetna joins the growing list of insurers that recognize the clinical effectiveness of AlloMap molecular expression testing.
